Rexahn Pharmaceuticals, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Rockville MD United States (2001)
Status: Acquired by Ocuphire Pharma, Inc. (2020)

Organization Overview

First Clinical Trial
2008
NCT00693056
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (2)

Key: Rexahn Pharmaceuticals, Inc. (0) Acquired (2)

phentolamine mesylate (regitine) (9 trials)

pilocarpine (ocusert) (2 trials)

Drugs in Phase 2 Trials (6)

Key: Rexahn Pharmaceuticals, Inc. (0) Acquired (6)

apx3330 (1 trial)

clavulanate (Augmentin) (3 trials)

everolimus (zortress) (1 trial)

fluorocyclopentenylcytosine (2 trials)

gemcitabine (gemzar) (1 trial)

rx-0201 (2 trials)

Drugs in Phase 1 Trials (1)

Key: Rexahn Pharmaceuticals, Inc. (0) Acquired (1)

rx-5902 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Carcinoma, Renal Cell (Phase 2)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Disease (Phase 2)

Erectile Dysfunction (Phase 2)

Pancreatic Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 1)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: None
  • # of Trials: 18
  • # of Trial APIs: 9